Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/16824
Title: Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry
Austin Authors: Gibson, Peter G;Reddel, H;McDonald, VM;Marks, G;Jenkins, C;Gillman, A;Upham, J;Sutherland, Michael;Rimmer, J;Thien, F;Katsoulotos, GP;Cook, M;Yang, I;Katelaris, C;Bowler, S;Langton, D;Robinson, P;Wright, C;Yozghatlian, V;Burgess, S;Sivakumaran, P;Jaffe, A;Bowden, J;Wark, PAB;Yan, KY;Kritikos, V;Peters, M;Hew, M;Aminazad, A;Bint, M;Guo, M
Affiliation: Centre for Healthy Lungs, Department of Respiratory and Sleep Medicine, John Hunter Hospital, Hunter Medical Research Institute, University of Newcastle, Newcastle, New South Wales, Australia
Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
University of Sydney, Liverpool Hospital, Sydney, New South Wales, Australia
School of Nursing and Midwifery, University of Newcastle, Newcastle, New South Wales, Australia
Department of Respiratory Medicine, Liverpool Hospital, Sydney, New South Wales, Australia
Department of Thoracic Medicine, Concord Hospital, Sydney, New South Wales, Australia
Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria, Australia
Department of Respiratory Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia
Department of Respiratory and Sleep Medicine, Austin Hospital, Melbourne, Victoria, Australia
St Vincent's Clinic, Campbelltown Hospital, Sydney, New South Wales, Australia
Department of Respiratory Medicine, Box Hill Hospital, Melbourne, Victoria, Australia
St George Specialist Centre, Campbelltown Hospital, Sydney, New South Wales, Australia
Department of Immunology, Canberra Hospital, Canberra, Australian Capital Territory, Australia
Department of Thoracic Medicine, The Prince Charles Hospital, Brisbane, Queensland, Australia
Department of Respiratory and Sleep Medicine, Campbelltown Hospital, Sydney, New South Wales, Australia
Department of Respiratory and Sleep Medicine, Mater Adult Hospital, Brisbane, Queensland, Australia
Department of Thoracic Medicine, Frankston Hospital, Melbourne, Victoria, Australia
Department of Respiratory Medicine, Children's Hospital at Westmead, Sydney, New South Wales, Australia
Department of Respiratory Medicine, Nambour Hospital, Nambour, Queensland, Australia
Department of Respiratory and Sleep Medicine, St George Hospital, Sydney, New South Wales, Australia
QLD Children's Lung and Sleep Specialists, Brisbane, Queensland, Australia
Department of Respiratory Medicine, Gold Coast District Hospital, Gold Coast, Queensland, Australia
Department of Respiratory Medicine, Sydney Children's Hospital, Sydney, New South Wales, Australia
Department of Respiratory, Allergy and Sleep Medicine, Flinders Medical Centre, Adelaide, South Australia, Australia
Clinical Management, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia
Issue Date: Sep-2016
Publication information: Internal Medicine Journal 2016; 46(9): 1054-1062
Abstract: BACKGROUND: Severe asthma is a high impact disease. Omalizumab targets the allergic inflammatory pathway; however, effectiveness data in a population with significant comorbidities are limited. AIMS: To describe severe allergic asthma, omalizumab treatment outcomes and predictors of response among the Australian Xolair Registry participants. METHODS: A web-based post-marketing surveillance registry was established to characterise the use, effectiveness and adverse effects of omalizumab (Xolair) for severe allergic asthma. RESULTS: Participants (n = 192) (mean age 51 years, 118 female) with severe allergic asthma from 21 clinics in Australia were assessed, and 180 received omalizumab therapy. They had poor asthma control (Asthma Control Questionnaire, ACQ-5, mean score 3.56) and significant quality of life impairment (Asthma-related Quality of Life Questionnaire score 3.57), and 52% were using daily oral corticosteroid (OCS). Overall, 95% had one or more comorbidities (rhinitis 48%, obesity 45%, cardiovascular disease 23%). The omalizumab responder rate, assessed by an improvement of at least 0.5 in ACQ-5, was high at 83%. OCS use was significantly reduced. The response in participants with comorbid obesity and cardiovascular disease was similar to those without these conditions. Baseline ACQ-5 ≥ 2.0 (P = 0.002) and older age (P = 0.05) predicted the magnitude of change in ACQ-5 in response to omalizumab. Drug-related adverse events included anaphylactoid reactions (n = 4), headache (n = 2) and chest pains (n = 1). CONCLUSION: Australian patients with severe allergic asthma report a high disease burden and have extensive comorbidity. Symptomatic response to omalizumab was high despite significant comorbid disease. Omalizumab is an effective targeted therapy for severe allergic asthma with comorbidity in a real-life setting.
URI: http://ahro.austin.org.au/austinjspui/handle/1/16824
DOI: 10.1111/imj.13166
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/27350385
Type: Journal Article
Subjects: Allergy
Comorbidity
Omalizumab
Phenotype
Registry
Severe asthma
Appears in Collections:Journal articles

Show full item record

Page view(s)

4
checked on Dec 1, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.